Mason Street Advisors’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Mason Street Advisors’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-30,101	Closed	-$114K	–	1533
2020 Q1	$114K	Hold	30,101	–	–	﹤0.01%	1398
2019 Q4	$153K	Buy	30,101 +756	+3%	+$4K	﹤0.01%	1433
2019 Q3	$148K	Buy	29,345 +1,058	+4%	+$5.28K	﹤0.01%	1416
2019 Q2	$175K	Buy	28,287 +1,135	+4%	+$5.47K	﹤0.01%	1389
2019 Q1	$126K	Buy	27,152 +897	+3%	+$4.06K	﹤0.01%	1491
2018 Q4	$110K	Buy	26,255 +1,410	+6%	+$7.18K	﹤0.01%	1447
2018 Q3	$156K	Buy	24,845 +3,557	+17%	+$27.3K	﹤0.01%	1429
2018 Q2	$171K	Buy	21,288 +1,794	+9%	+$13.7K	﹤0.01%	1416
2018 Q1	$145K	Buy	19,494 +1,218	+7%	+$8.1K	﹤0.01%	1409
2017 Q4	$109K	Buy	18,276 +479	+3%	+$2.91K	﹤0.01%	1455
2017 Q3	$131K	Buy	17,797 +479	+3%	+$3.04K	﹤0.01%	1409
2017 Q2	$118K	Buy	17,318 +938	+6%	+$6.92K	﹤0.01%	1415
2017 Q1	$155K	Buy	+16,380	New	+$163K	﹤0.01%	1344

Other funds holding PGNX

ECM

Everence Capital Management Goshen, Indiana $1.64B AUM 26.46% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Mason Street Advisors's PGNX Position: Q2 2020 in Review

Mason Street Advisors sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 30,101 shares — an estimated $114K sold.

Mason Street Advisors first reported a position in PGNX in Q1 2017 and held it in 13 quarters. The position peaked at $175K in Q2 2019. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

Mason Street Advisors reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
Mason Street Advisors sold 30,101 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $114K.
Mason Street Advisors first reported a position in Progenics Pharmaceuticals Inc in Q1 2017 and held it in 13 quarters.
Mason Street Advisors's Progenics Pharmaceuticals Inc position peaked at $175K in Q2 2019.
3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on Mason Street Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.